Biochemical value of microRNA-223 in colon cancer Egyptian patients | ||||
| Azhar International Journal of Pharmaceutical and Medical Sciences | ||||
| Article 18, Volume 5, Issue 1, January 2025, Page 216-222 PDF (259.1 K) | ||||
| Document Type: Original research articles | ||||
| DOI: 10.21608/aijpms.2024.230584.1233 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sara M Muhammad  1; Abeer I. Abd El-Fattah2; abeer Ismail3; Muhammad S. Mostafa4; Ola E. Elazazy 5
| ||||
| 1Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt. | ||||
| 2Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Girls), Al-Azhar University | ||||
| 3Clinical and Chemical Pathology Department, National Cancer Institute (N.C.I.), Cairo University | ||||
| 4Medical Oncology Department, Faculty of Medicine, Cairo University | ||||
| 5Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC) | ||||
| Abstract | ||||
| One of the highly prevalent cancers worldwide is Colorectal cancer (CRC). MicroRNAs (miRNAs) are small non-coding molecules. A candidate miRNA whose expression was correlated with tumor aggressiveness and poor prognosis in colon cancer patients is miR-223. Furthermore, miR-223 could be used as a diagnostic marker for CRC and a therapeutic target as well. The present study aimed to examine the potential of miR-223 to diagnose CRC in Egyptian patients and correlate its level with carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19-9), and different stages of colon cancer. The study included 60 individuals selected from the National Oncology Institute; the subjects were classified into two groups: 20 healthy control group volunteers and 40 colon cancer patients group, which were subdivided into 3 sub-groups according to severity: Low-risk colon cancer group which included stages (zero-one): 15 subjects, Intermediate-risk colon cancer group which includes stage (two): 13 subjects and High-risk colon cancer group which includes stages (three-four): 12 subjects Evaluation of serum levels of CEA and CA 19.9 was done through sandwich ELISA and miR-223 was done through RT-PCR. There was a significant increase in miR-223 expression levels in patient groups compared to the control group. There was a strong positive significant correlation between the expression levels of miR-223 and different degrees of risk. Moreover, the serum levels of miR-223 had an Area under the Curve (AUC) value of 0.997, with 100% sensitivity and specificity of 90% at p<0.05. Thus, miR-223 could be used as a diagnostic and prognostic marker in CRC. | ||||
| Keywords | ||||
| CRC; miR-223; miRNA; CEA; CA 19-9; biomarker | ||||
|
Statistics Article View: 40 PDF Download: 15 |
||||
